EFTA00665300.pdf
PDF Source (No Download)
Extracted Text (OCR)
From: Boris Nikolic
To: "Jeffrey Epstein (I
<
Subject: FW: Materials at request of David Rubenstein
Date: Tue, 04 Feb 2014 07:51:42 +0000
Attachments: NaviMed_Global_PPM_Draft_4-18-11_pdf
PPM from the Carlyle
Check out 10 years plus 31
Board of Advisors structure etc very similar.
2.5% fee.
Co-investments, parallel funds etc.
B
From: Ryan Schwarz [mailto:
Sent: Wednesday, April 27, 2011 8:17 AM
To: Boris Nikolic
Subject: RE: Materials at request of David Rubenstein
Boris,
Good to see you again in Washington a couple weeks back. I hope you've been well.
The placement memo for our new global healthcare fund is now pretty much finalized, and David and I wanted to share it
with you. I've attached it to this email.
very much like to discuss the fund with you further, and to that end • be
happy to meet with you in Seattle (or elsewhere) if that would be desirable and would facilitate a discussion.
Best regards,
Ryan
Ryan M. Schwarz
Managing Director
THE CARLYLE GROUP
1001 Pennsylvania Ave. =.
Washington, DC 20004
direct
mobile
From: Boris Nikolic [mailto:
Sent: Friday, March 11, 2011 2:21 AM
EFTA00665300
To: Ryan Schwarz
Subject: RE: Materials at request of David Rubenstein
Hi Ryan,
Great meeting you earlier in day.
I made my flight but barely. There was no traffic. It was a luck.
Your fund is very interesting and there are a number of synergies. I look forward to discussing it in more details with you
as you are developing it.
Please keep me posted.
If you have any plans of visiting Seattle, please let me know
All the best
Boris
From: Ryan Schwarz [mailto:
Sent: Wednesday, March 09, 2011 11:28 AM
To: Boris Nikolic
Subject: Materials at request of David Rubenstein
Boris,
David asked me to send you the two attached documents before our meeting tomorrow. One is a high-level concept piece
on the global healthcare venture fund idea that we prepared to help David introduce the concept to folks around Carlyle.
It provides an overview of the market opportunity as we see it, though of course with much less detail around investment
strategy and emphases than will be included in the eventual fund placement memo and presentation. The other is a
confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market
drug for severe sepsis.
I look forward to seeing you in the morning.
Ryan
Ryan M. Schwarz
Managing Director
THE CARLYLE GROUP
1001 Pennsylvania Ave. =.
Washington, DC 20004
direct
mobile
< CONFIDENTIALITY NOTICE >
The information contained in this transmission is intended only for the person or entity to which it is addressed
EFTA00665301
and may contain confidential, trade secret and/or privileged material. If you are not the intended recipient of this
information, do not review, retransmit, disclose, disseminate, use, or take any action in reliance upon, this
information. If you received this transmission in error, please contact the sender and destroy all printed copies
and delete the material from all computers.
< CONFIDENTIALITY NOTICE >
The information contained in this transmission is intended only for the person or entity to which it is addressed
and may contain confidential, trade secret and/or privileged material. If you are not the intended recipient of this
information, do not review, retransmit, disclose, disseminate, use, or take any action in reliance upon, this
information. If you received this transmission in error, please contact the sender and destroy all printed copies
and delete the material from all computers.
EFTA00665302
Document Preview
PDF source document
This document was extracted from a PDF. No image preview is available. The OCR text is shown on the left.
This document was extracted from a PDF. No image preview is available. The OCR text is shown on the left.
Extracted Information
Document Details
| Filename | EFTA00665300.pdf |
| File Size | 121.4 KB |
| OCR Confidence | 85.0% |
| Has Readable Text | Yes |
| Text Length | 3,624 characters |
| Indexed | 2026-02-11T23:24:09.888336 |